@FiercePharma: FDA warning letter requires early exec presence, artful response. Article | Follow @FiercePharma
> Genzyme, the embattled biotechnology company, says it has created the new position of chief operating officer and appointed executive vice president David Meeker to the post. Release | Report
> For more than two months in late 2008, private investigators working for generics maker Amphastar gathered information on CDER's Janet Woodcock, unearthing details about her family and re-tracing her steps on a business trip to Thailand. Report
> Boehringer Ingelheim's prostate drug Flomax, previously available only by prescription, will now be sold over the counter in U.K. pharmacies. Report
> Duodart, a two-in-one prostrate drug from GlaxoSmithKline, has been approved in Europe. Report
> Allergan, the Irvine-based maker of Botox and other drugs, had its outlook raised by Fitch Ratings. Report
Biotech News
@FierceBiotech: New Boehringer fund to invest $135M in biotech, start-ups. Report | Follow @FierceBiotech
@JohnCFierce: Two things to highlight on this Glaxo/Isis deal. Glaxo is showing its love of rare diseases, and Isis gets marks for staying in control to proof-of-concept. | Follow @JohnCFierce
> ArQule shares skyrocket on promising Phase II lung cancer data. Report
> Vivus hands back rights to testosterone therapy. Item
> Experts fear gene patent ruling's impact on biotech. Story
> Eisai pursues blockbuster approvals for breast cancer drug. Article
> Isis bags $1.53B rare disease development deal with GSK. Report
Medical Device News
> Report: Feds scrutinizing Boston Scientific recall. Article
> Boston Scientific's CEO gets $33.4 million; Baxter chief's pay falls. Story
> A Johnson & Johnson unit received an offer from private-equity firm GTCR Golder Rauner for its breast-care business. Report
And Finally... The ability to show the quality of connections within the brain is leading to better understanding of creativity, intelligence and mental illness. Report